Growth Hormone Research Peptides
Compare CJC-1295 No DAC, Ipamorelin and Tesamorelin by material, signalling pathway and study outcome. Start with the exact form described in the research.
Compare the listings3 products
- Growth Hormone

CJC-1295 No DAC
Growth hormone research. Learn what No DAC means and why the exact form matters.
From $49.99In stock
- Growth Hormone

Ipamorelin
Growth hormone release research, with a clear explanation of the signalling pathway.
$74.99In stock
Compare the three growth hormone research listings
Growth-hormone research includes several signalling questions. A compound investigated for stimulating hormone release is different from supplying growth hormone itself. The pathway, material identity and measured endpoint all matter when reading a product description or a publication.
CJC-1295 No DAC, ipamorelin and tesamorelin appear together in this catalogue because they are discussed around this broad research area. They should still be compared individually. A shared category is a navigation aid, not a statement that they have the same composition, duration, evidence or experimental use.
Start by identifying the material and the publication you are trying to understand. The product page provides current options and specifications. The research profile and comparison guides explain the distinctions behind the names. Keeping those roles separate makes both the catalogue and the science easier to use.
| Compound | Research context | Identity or evidence check |
|---|---|---|
| CJC-1295 No DAC | GHRH-related signalling under the supplier's No DAC designation | Confirm sequence, terminal form and modifications; do not apply a long-acting DAC study by name alone. |
| Ipamorelin | Growth-hormone secretagogue research | Identify the receptor context and the experimental model in the source. |
| Tesamorelin | Growth-hormone-releasing hormone analogue research | Read the actual study population and distinguish visceral-fat endpoints from other outcomes. |
GHRH and ghrelin receptor pathways
GHRH stands for growth-hormone-releasing hormone. It is one of the terms that appears in discussions of CJC-related materials and tesamorelin. Ipamorelin is discussed in a different secretagogue-receptor context. Similar downstream topics do not erase the difference in how the compounds are investigated.
An early ipamorelin paper described pharmacology using laboratory and animal models. That is valuable background for understanding the compound's research history, but it should not be presented as a universal personal outcome. The broader secretagogue guide explains the terminology without turning a mechanism into a promise.
| Material or research context | Pathway to check | Outcome in cited literature |
|---|---|---|
| Long-acting CJC-1295 | GHRH-related signalling. | Growth hormone and IGF-1 over time. |
| Ipamorelin | Ghrelin receptor signalling. | Exposure and growth hormone response. |
| Tesamorelin | GHRH-related signalling. | Visceral-fat imaging in a defined population. |
CJC-1295 No DAC and the long-acting study
The exact name and supplied form matter. A publication investigating long-acting CJC-1295 should not automatically be used to describe a listing designated No DAC. Do not transfer a duration of action, pharmacokinetic value or study conclusion from one material to another without a verified identity match.
A useful comparison states the distinction plainly and leaves undocumented fields unconfirmed. The current CJC-1295 No DAC vs tesamorelin guide separates the reference information from the available product options, so the identity check is not obscured by price or stock.
Read tesamorelin evidence in its study context
Research on tesamorelin includes a trial in people with HIV-associated abdominal fat accumulation. The population and the way visceral adipose tissue was measured are central to understanding that source. Visceral fat, subcutaneous fat and total body weight are different concepts, so one should not silently replace another in a summary.
The evidence belongs to the study formulation and conditions. It is separate from the identity and documentation of a catalogue research material. The tesamorelin profile introduces the source literature and the limitations that should remain visible when the compound appears in a broader comparison.
Check the fields that affect interpretation
For the material, check its exact name, stated form and modifications where documented, package amount and matching lot record. For the research, check the model or population, comparator, measurement and limits of the conclusion. A similar abbreviation is not a replacement for either check.
The specifications guide explains why a field should remain unconfirmed if the supporting record does not establish it. Lab Results is the route to published records when available; the existence of research on a compound is not itself a batch test.
Check the full compound name
Growth hormone is a hormone; the listed materials concern its release or associated signalling. Preserve the No DAC qualifier for CJC-1295 and do not borrow duration or identity claims from a different CJC formulation.
These collections organise research interests; they are not personal treatment recommendations or promises of an outcome. Peptide Blends is a product format.
A closer look at growth hormone research
Growth hormone research in plain language
Growth hormone signalling involves communication between the brain, pituitary gland and other tissues. Compounds discussed around this system can act through different receptors, and the resulting research questions may concern a hormone response, a downstream marker or a body-composition endpoint. Ipamorelin and tesamorelin belong in this conversation for different mechanistic reasons. Neither a shared category nor a larger vial amount makes them equivalent. Start with the receptor pathway, then check the experiment and the population before interpreting the result.
Ipamorelin and tesamorelin use different routes
Ipamorelin is a growth hormone secretagogue associated with ghrelin-receptor signalling. Tesamorelin is an analogue of growth hormone-releasing hormone. A secretagogue is a substance that stimulates secretion; it is not a synonym for supplied growth hormone. These distinctions help explain why a comparison should describe the mechanism before discussing outcomes. The existing comparison covers the two pathways and links to the individual product listings. Their package sizes and prices describe the supplied research listings, not equivalent biological activity.
Keep study populations and endpoints visible
A measured increase in hormone release answers a different question from a change in body composition. A result obtained in animals does not carry the same interpretation as a controlled human study, and a clinical trial in a defined patient group cannot automatically be generalised to healthy adults. Read the inclusion criteria and primary outcome, and keep exploratory findings separate from the main question. Tesamorelin’s research profile provides context for its studied population. Use the source paper when you need to understand the design rather than relying on a short category label.
A practical reading order is to identify the compound, compare a related listing, then read the underlying study and the product documentation. The Research Library explains the terminology. Use the COA checklist to distinguish sample identity, analytical purity and measured content. The evidence-reading guide explains how to keep a laboratory observation separate from a result measured in people.
Growth Hormone questions
Does this category contain growth hormone itself?
The featured materials are discussed in growth-hormone signalling research. That does not make them the same material as growth hormone.
Can I apply a long-acting CJC-1295 study directly to No DAC?
Do not assume that. Confirm the exact material and modifications before applying findings from a different form.
Are ipamorelin and tesamorelin interchangeable?
No equivalence should be assumed. Their identities and research contexts should be compared separately.
Does a visceral-fat finding describe every weight-related outcome?
No. The tissue measurement and study population define the result. Read the actual endpoint rather than substituting a broader claim.
What if a specification field is missing?
Treat it as unconfirmed and ask about the source documentation. Do not fill it from another supplier or a similarly named research material.
What does a growth hormone response tell me about clinical outcomes?
It describes a hormone marker in the study. A clinical or imaging outcome needs a study that actually measured it in the relevant participants.
Follow the research
Sources and study context
PRIMARY SOURCES: Raun et al., European Journal of Endocrinology (1998), PMID 9849822, Read the original study; Teichman et al., JCEM (2006), PMID 16352683, Read the original study (long-acting CJC-1295, not evidence of identity for a No DAC listing); Falutz et al., NEJM (2007), PMID 18057338, Read the original study.

